Page 279 - Pagetit

NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE

provocation studies 224
Ion channels 30, 31
IPC-1010, cocaine vaccine 92

Justice, distributive, biomedical ethics 217, 226

Kappa receptors 80, 137
Ketamine 104, 178–179
Khat (Catha edulis), cathinone 94

Legal coercion, treatment studies, ethical issues 232–235
Limbic system 25
dopamine pathway 44, 106
mesolimbic system and VTA 174–175
and substance dependence 187–188
Linkage studies 125, 127–128
dependence 139
d-Lysergic acid amine (LSA) 104
serotonin autoreceptor agonist 109
Lysergic acid diethylamide (LSD) 104–106

Magnetic resonance imaging (MRI) 39–40
MAOI, see Monoamine oxidase inhibitor
MDMA, see 3,4-Methylenedioxymethamphetamine
Mental illness, and psychoactive substance use 169–207
Mescaline 104
Mesencephalon 21
Methadone
treatment of opioid dependence 81–84
substitution therapy 82
Methamphetamine (see also Amphetamines)
development of tolerance 54
N-Methyl-D-aspartate (NMDA), glutamate receptor antagonist, phency-
clidine (PCP) 109, 178–179
Methylenedioxyamphetamine (MDA) 104
3,4-Methylenedioxymethamphetamine (MDMA) (see also Ecstacy) 96–100
behavioural effects 97–99
Methylphenidate, see Amphetamines
Models of dependence 231–232
animal studies 219
ethical issues 209, 218–219
Monoamine oxidase A 144
Monoamine oxidase inhibitor (MAOI), placebo in smoking studies 181
Motivation 48
Motivational enhancement therapy 60

258

Index 258 19.1.2004, 11:52